<DOC>
	<DOCNO>NCT02346955</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability humanize IgG4 ( kappa ) isotype monoclonal antibody CEACAM1 ( CM-24 [ MK-6018 ] ) , administer intravenously monotherapy combination Pembrolizumab ( MK-3475 ) , participant select advanced recurrent malignancy . Escalating multiple dos evaluate determine recommend dose Phase 2 clinical study .</brief_summary>
	<brief_title>Study CM-24 ( MK-6018 ) Alone In Combination With Pembrolizumab ( MK-3475 ) Participants With Selected Advanced Recurrent Malignancies ( MK-6018-001 )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Males female ≥18 year age Participants Dose Escalation portion must one follow advanced recurrent malignancy : gastrointestinal ( colorectal gastric ) ; ovarian ; melanoma ; nonsmall cell lung adenocarcinoma ; bladder . Participants Monotherapy Expansion Cohort must one follow advanced recurrent malignancy : cutaneous melanoma show primary progression follow treatment antiprogrammed cell death ( PD ) antiPDL1 regimen ; antiPD1 antiPDL1 treatmentnaïve colorectal gastric cancer , include gastroesophageal junction cancer Siewert Type II Type III . Participants Combination Expansion Cohorts must one follow advanced recurrent malignancy : nonsmall cell lung adenocarcinoma cutaneous melanoma show primary progression follow treatment antiPD1 antiPDL1 regimen ; antiPD1 antiPDL1 treatmentnaïve colorectal gastric cancer , include gastroesophageal junction cancer Siewert Type II Type III . Melanoma BRAF V600E V600K mutationpositive melanoma must progress , intolerant , prior BRAF MEKinhibitor therapy Must least 1 measurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 progress new tumor since last antitumor therapy Must adequate hematologic , renal , liver function Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Females must pregnant ( negative human chorionic gonadotropin test within 72 hour prior receive first dose study medication ) breastfeed Women childbearing potential male participant must agree use adequate contraception throughout study 180 day study treatment An estimate life expectancy least 3 month Must consent provide archival tumor biopsy sample time point screen study exit Must consent allow acquisition new tissue biopsy sample study History severe hypersensitivity reaction immune related adverse event monoclonal antibody History active malignancy within prior 2 year History insulindependent uncontrolled Diabetes Mellitus History inflammatory bowel disease Autoimmune disorder Known HIV and/or Hepatitis B C infection Known systemic bleeding platelet disorder Receipt live vaccine 4 week ( 28 day ) study History evidence noninfectious pneumonitis require steroid current pneumonitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Oncology</keyword>
	<keyword>cCAM Biotherapeutics Ltd</keyword>
	<keyword>Immunomodulatory therapy</keyword>
	<keyword>CM-24</keyword>
	<keyword>Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 ( CEACAM1 )</keyword>
	<keyword>NSCLC ( adenocarcinoma )</keyword>
	<keyword>Uveal</keyword>
	<keyword>Acral</keyword>
	<keyword>Mucosal</keyword>
	<keyword>Cutaneous</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Gastric</keyword>
	<keyword>Ovarian</keyword>
	<keyword>Bladder</keyword>
	<keyword>MK-6018-001</keyword>
</DOC>